EA202190088A1 - СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1 - Google Patents
СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1Info
- Publication number
- EA202190088A1 EA202190088A1 EA202190088A EA202190088A EA202190088A1 EA 202190088 A1 EA202190088 A1 EA 202190088A1 EA 202190088 A EA202190088 A EA 202190088A EA 202190088 A EA202190088 A EA 202190088A EA 202190088 A1 EA202190088 A1 EA 202190088A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- methods
- cd3xmuc16
- treatment
- new policy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190088A1 true EA202190088A1 (ru) | 2021-03-22 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190088A EA202190088A1 (ru) | 2018-06-21 | 2019-06-20 | СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11254752B2 (https=) |
| EP (2) | EP4424712A3 (https=) |
| JP (1) | JP7403480B2 (https=) |
| KR (1) | KR102870971B1 (https=) |
| CN (1) | CN112312970B (https=) |
| AU (1) | AU2019290170B2 (https=) |
| BR (1) | BR112020025476A2 (https=) |
| CA (1) | CA3103887A1 (https=) |
| CL (1) | CL2020003256A1 (https=) |
| DK (1) | DK3810281T3 (https=) |
| EA (1) | EA202190088A1 (https=) |
| ES (1) | ES2984972T3 (https=) |
| FI (1) | FI3810281T3 (https=) |
| HU (1) | HUE067985T2 (https=) |
| IL (1) | IL279251B2 (https=) |
| MA (2) | MA71708A (https=) |
| MX (2) | MX2020013905A (https=) |
| MY (1) | MY202134A (https=) |
| PH (1) | PH12020552115A1 (https=) |
| PL (1) | PL3810281T3 (https=) |
| PT (1) | PT3810281T (https=) |
| RS (1) | RS65886B1 (https=) |
| SG (1) | SG11202012137UA (https=) |
| TW (2) | TW202504917A (https=) |
| WO (1) | WO2019246356A1 (https=) |
| ZA (1) | ZA202007599B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| IL300835A (en) * | 2020-09-02 | 2023-04-01 | Genmab As | Antibody therapy |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| WO2022197907A2 (en) * | 2021-03-18 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| EP4397320A1 (en) | 2021-08-31 | 2024-07-10 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product |
| EP4437003A1 (en) * | 2021-11-24 | 2024-10-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| US20230312718A1 (en) * | 2022-01-07 | 2023-10-05 | Regeneron Pharmaceuticals, Inc | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies |
| JP2025504795A (ja) | 2022-01-10 | 2025-02-19 | ナンチン リーズ バイオラブス カンパニー，リミティド | 抗体及びその用途 |
| US20250195645A1 (en) * | 2022-03-16 | 2025-06-19 | Daiichi Sankyo Company, Limited | Combination of multispecific molecule and immune checkpoint inhibitor |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| LT3394103T (lt) * | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| TWI910495B (zh) | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY203000A (en) * | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
-
2019
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-19 TW TW108121196A patent/TWI890661B/zh active
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 KR KR1020217000649A patent/KR102870971B1/ko active Active
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 AU AU2019290170A patent/AU2019290170B2/en active Active
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 IL IL279251A patent/IL279251B2/en unknown
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 MY MYPI2020006505A patent/MY202134A/en unknown
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en not_active Ceased
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
-
2020
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 MX MX2025008444A patent/MX2025008444A/es unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190088A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1 | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| EA201891495A1 (ru) | Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза | |
| PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| EP4644427A3 (en) | Manabodies and methods of using | |
| IL286473A (en) | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer | |
| EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| MX2020002301A (es) | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| MX2022008421A (es) | Anticuerpo anti-galectina-9 y usos del mismo. | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2024008055A (es) | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. | |
| MX2025001239A (es) | Métodos para tratar cáncer de próstata resistente a la castración metastasico con anticuerpos biespecíficos anti-psma x anti-cd28 en combinación con anticuerpos anti-pd-1 | |
| MX2024006187A (es) | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. | |
| PH12020551451A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| ZA202106551B (en) | Anti-bag2 antibody and methods of treating cancer | |
| EA202090696A1 (ru) | Комбинированная терапия рака поджелудочной железы комбинацией анти-csf1r и анти-pd-1 антител |